- 期刊
- OpenAccess
Exemestane in the Adjuvant Treatment of Breast Cancer in Postmenopausal Women
並列摘要
Exemestane is an irreversible inhibitor of the aromatase enzyme, which is a key component in the production of estrogen. The majority of breast cancers are sensitive to the proliferative effects of estrogen. Exemestane is approved for the adjuvant treatment of postmenopausal women with breast cancer after 2 to 3 years of tamoxifen therapy, based on a 32% improvement in disease-free survival compared with 5 years of tamoxifen alone (P＜ 0.001). Exemestane has also shown clinical benefits as an upfront therapy. The safety profile of exemestane shares some side effects with tamoxifen (hot flashes and arthralgia), but is not associated with an increased risk of endometrial cancer or thromboembolic events. This review will discuss in detail the efficacy and safety of exemestane in early breast cancer.
延伸閱讀
- 歐子綺、常傳訓、黃純文、陳楚杰、呂友敏（2019）。Effects of Tamoxifen Treatment Time on Breast Cancer Patient Survival。醫務管理期刊，20(1)，1-14。https://doi.org/10.6174/JHM.201903_20(1).1
- 張嘉哲（2018）。Review of Advances in the Treatment of Advanced Estrogen-receptor-positive Breast Cancer。內科學誌，29(6)，381-392。https://doi.org/10.6314/JIMT.201812_29(6).05
- Mukohara, T. (2011). Role of HER2-Targeted Agents in Adjuvant Treatment for Breast Cancer. Chemotherapy Research and Practice, 2011(), 127-138. https://doi.org/10.1155/2011/730360
- Bonilla, A. L., & Glück, F. S. A. S. (2013). Clinical Utility of Aromatase Inhibitors as Adjuvant Treatment in Postmenopausal Early Breast Cancer. Clinical Medicine Insights: Women’s Health, (2013), 1-11. https://doi.org/10.4137/CMWH.S8692
- Guiu, S., Reynier, M. A. M., Toure, M., & Coudert, B. (2013). Predictive Factors of Response in HER2-Positive Breast Cancer Treated by Neoadjuvant Therapy. Journal of Oncology, 2013(), 155-163. https://doi.org/10.1155/2013/854121